Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

Saved in:
Bibliographic Details
Main Authors: Conchon,Monika, Freitas,Carla Maria Boquimpani de Moura, Rego,Maria Aparecida do Carmo, Braga Junior,José Wilson Ramos
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-84842011000200012
record_format ojs
spelling oai:scielo:S1516-848420110002000122011-06-13Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaConchon,MonikaFreitas,Carla Maria Boquimpani de MouraRego,Maria Aparecida do CarmoBraga Junior,José Wilson Ramos Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy Drug toxicity Drug interactions Gastrointestinal tract/drug effects Drug resistance, neoplasm Pyrimidines Interferonalpha/administration & dosage Piperazines/therapeutic use Clinical Trial Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.33 n.2 20112011-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012en10.5581/1516-8484.20110034
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Conchon,Monika
Freitas,Carla Maria Boquimpani de Moura
Rego,Maria Aparecida do Carmo
Braga Junior,José Wilson Ramos
spellingShingle Conchon,Monika
Freitas,Carla Maria Boquimpani de Moura
Rego,Maria Aparecida do Carmo
Braga Junior,José Wilson Ramos
Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
author_facet Conchon,Monika
Freitas,Carla Maria Boquimpani de Moura
Rego,Maria Aparecida do Carmo
Braga Junior,José Wilson Ramos
author_sort Conchon,Monika
title Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_short Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_full Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_fullStr Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_full_unstemmed Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_sort dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
description Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
publisher Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012
work_keys_str_mv AT conchonmonika dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia
AT freitascarlamariaboquimpanidemoura dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia
AT regomariaaparecidadocarmo dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia
AT bragajuniorjosewilsonramos dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia
_version_ 1756423528032239616